|
Resolution: standard / high Figure 3.
Clinical adverse event discontinuation: placebo, etoricoxib, and individual NSAIDs. Shown are the percentages of patients remaining after clinical adverse event (AE) discontinuation in studies conducted over 4 to 12 weeks with placebo, etoricoxib, and individual nonsteroidal anti-inflammatory drugs (NSAIDs). OA, osteoarthritis; RA, rheumatoid arthritis.
Moore et al. Arthritis Research & Therapy 2008 10:R53 doi:10.1186/ar2422 |